Tisotumab vedotin-tftv (Tivdak)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Tivdak · Reconstitution and dilution
- Preparation
- For each 40 mg vial, add 4 mL sterile water for injection (10 mg/mL). Dilute to 0.7-2.4 mg/mL in 0.9% sodium chloride, 5% dextrose or lactated Ringer's.
- Administration and handling
- Use a 0.2-micron in-line filter for the 30-minute infusion. Follow the ocular premedication and eye-care requirements in the full label.
Product and source details
SEAGEN INC. · BLA761208
Product NDC: 51144-003
SPL effective 2026-10-16 | SPL version 11. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.